Highlights: A new guideline by the American Academy of Neurology says psychological interventions are possibly effective in helping people achieve freedom from functional seizures. Functional seizures, previously known as psychogenic nonepileptic seizures or non-epileptic attack disorder, can look or feel like seizures from epilepsy or fainting, but they have their own typical features. The guideline says appropriate treatment may decrease the frequency of functional seizures, decrease anxiety a

WASHINGTON, Dec. 18, 2025 /PRNewswire/ -- The American Pharmacists Association (APhA) participated in a White House ceremony marking the rescheduling of marijuana as a Schedule III drug. Marijuana's Schedule I classification imposes strict regulatory requirements that make it difficult for researchers and scientists to obtain it for study. APhA believes that moving marijuana to Schedule III will help accelerate research into its medicinal applications and potentially lead to safer and more effec

Leading researcher in inflammation, immunology, and drug metabolism to guide development of precise, lab-verified psilocybin for regulated therapeutic use. VAIL VALLEY, Colo., Dec. 18, 2025 /PRNewswire/ -- Psylutions, Colorado's first licensed cultivator and manufacturer of psilocybin serving over half of the licensed healing centers, clinicians, and researchers in the state, today announced the appointment of Nichole R. Klatt, Ph.D., to its Advisory Board. Dr. Klatt is Professor of Surgery and

Recent Morocco Lecture Addresses Viral Pop-Culture Phrase Referencing PRP Vaginal Injections FAIRHOPE, Ala., Dec. 18, 2025 /PRNewswire/ -- Charles Runels, MD, founder of the Cellular Medicine Association (CMA), recently delivered an international medical lecture in Morocco addressing the science behind a viral pop-culture phrase — "Revenge Vagina" — and its connection to a real, peer-reviewed medical procedure known as the O-Shot®. Continue Reading Charles Runels, MD Science of the Revenge Vag

The Company confirms it is assessing U.S. licensing pathways for its Canna Cabana retail brand NuLeaf Naturals and FAB CBD evaluating Medicare-aligned product categories CALGARY, AB, Dec. 18, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, today welcomed the Executive Order issued by the White House advancing the rescheduling

Trump Administration's Rescheduling Opens New Avenues for Research, Medical Advancement, and Investment STAMFORD, Conn., Dec. 18, 2025 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today applauds the Trump Administration's action to implement the most impactful federal cannabis reform of the past fifty years by rescheduling cannabis as a Schedule III substance under the Controlled

Reclassification Eases Barriers to Research and Removes Punitive 280E Tax Burden TALLAHASSEE, Fla., Dec. 18, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., applauds action taken by the Trump Administration to reclassify marijuana to Schedule III under the Controlled Substances Act. "This bold and historic direction from President Trump represents long overdue change and a major mi

Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement will help advance new radioconjugate therapies capable of precisely targeting and destroying cancer cells LANSING, Mich., Dec. 18, 2025 /PRNewswire/ -- Niowave Inc., a U.S.- based global leader in medical radioisotope production, today announced the expansion of its existing supply agreement with AstraZeneca, a global biopharmaceutical company, to a 10-year commi

Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight's treatment platform No patient safety issues were reported The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®) and diagnostic (uTRACE®) platforms COPENHAGEN, Denmark, Dec. 18, 2025 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) today announced the successful and safe dosing of the first p

PARIS, Dec. 18, 2025 /PRNewswire/ -- Peptinov today announced the publication of the Phase 1 clinical results for PPV-06, its first-in-class active immunotherapy targeting IL-6, in the peer-reviewed journal Nature Communications. The randomized, double-blind, placebo-controlled study was conducted in 24 patients with inflammatory knee osteoarthritis under the supervision of Prof. François Rannou at Cochin Hospital (AP-HP, Paris). The study met its primary objective. PPV-06 demonstrated an excell